- News & Analysis
- Home
- Latest News
- Reports
- Podcast
- The CVC Funding Round Database
- The CVC Directory
- University
- Video
- Subscribe
- Newsletters
- Events
Page 118
Pinterest proceeds to IPO stage
Rakuten is among the investors in line for an exit following Pinterest’s decision to file confidentially for an initial public offering expected to value it at more than $12bn in the next four months.
Feb 22, 2019Ucommune seeks home in public markets
The workspace operator is reportedly seeking a $3bn valuation in a US IPO that would allow a host of corporates including several real estate developers to exit.
Feb 21, 2019SoYoung looks to mature with $300m IPO
Tencent is in line for an exit after China-based cosmetic surgery booking platform SoYoung confidentially filed to go public in the US in an offering that could raise $300m.
Feb 20, 2019Stealth Bio shifts to $78m IPO
Nan Fung-backed mitochondrial therapy developer Stealth BioTherapeutics floated at the foot of its range to raise $78m, having disclosed $100m in financing last June.
Feb 19, 2019Douyu cues up $500m IPO
Tencent-backed Douyu has confidentially filed to go public in the US, following another Chinese livestreaming platform, Huya, which floated last year.
Feb 14, 2019Peloton begins IPO cycle
Comcast and Grace Beauty-backed interactive exercise platform Peloton Interactive is interviewing banks for an offering slated for the second half of 2019.
Feb 13, 2019Harpoon snags public markets listing
The Taiho and Eli Lilly-backed immunotherapy developer floated in the middle of its range to raise $75.6m, valuing it at about $334m.
Feb 11, 2019Stealth to make stock market appearance
Nan Fung-backed biopharmaceutical company Stealth Bio has filed for an IPO that could bring in almost $87m if it floats at the top of the range.
Feb 11, 2019Choi chosen to head investment at Netmarble
Netmarble’s head of corporate strategy and senior vice-president, Chanseok Choi, has been promoted to managing director and head of investment.
Feb 8, 2019Alector achieves $176m IPO
The AbbVie, Eli Lilly, Amgen, Merck & Co and Alphabet-backed neurodegenerative disease drug developer is floating in the middle of its range.
Feb 7, 2019About us
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
Navigation
test regLogin
Not yet subscribed?
We use cookies to enhance your browsing experience and analyse our traffic. By clicking "Accept All", you consent to our use of cookies. Accept Read MorePrivacy & Cookies PolicyPrivacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.


